At a glance
ClinicalIndex Comparison RecordN/ACompleted· 116 enrolled
Drug / intervention
Cholecalciferoldrug
Likely dose
Cholecalciferol 50,000 IUfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Immunologic Impact of Vitamin D Repletion in Hemodialysis Patients: A Randomized Controlled Trial
In Brief
A clinical study evaluating Cholecalciferol for Vitamin D Deficiency and End-stage Renal Disease. Completed, enrolled 116 participants across 1 site.
Detailed Summary
Dialysis patients often suffer from defects in their immune system (that part of the body which fights infection). Evidence suggests that Vitamin D deficiency may have a negative effect on immunity, and many dialysis patients are deficient in Vitamin D. We believe that by giving Vitamin D to dialysis patients who are deficient, we may help improve their immune system. This study will test that idea.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsVitamin D Deficiency, End-stage Renal Disease
CountriesUnited States
Timeline
N/ACompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartAug 2010
First PostedAug 2010
Primary CompletionAug 2013
TodayJul 2026
First PostedAug 5, 2010
Enrollment StartAug 1, 2010
Primary CompletionAug 1, 2013
TodayJul 2, 2026
Enrollment to primary: 3 yearsPosted 15.9 years ago
Interventions
Cholecalciferoldrug
50,000 IU PO weekly x 6 weeks